NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 VALIANT LABORATORIES LIMITED - FINANCIAL SUMMARY ANNUAL REPORT FY 2025-26 --- HEADLINE NUMBERS STANDALONE BASIS • Total Revenue: ₹31,976 Lakhs • EB | 2026-09-03 |
| Quarterly results · Q1 FY27 VALIANT LABORATORIES LIMITED - FINANCIAL SUMMARY Q1 FY2026-27 Results (Quarter ended June 30, 2026) --- HEADLINE NUMBERS • Standalone Revenue from | 2026-08-10 |
| Quarterly results · Q4 FY26 VALIANT LABS DOCUMENT SUMMARY HEADLINE NUMBERS • No specific financial figures provided in this document • Document dated July 4, 2025 relates to fin | 2026-06-25 |
| Quarterly results | 2026-06-01 |
| Quarterly results · Q3 FY26 VALIANT LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS STANDALONE (9 months ended 31-Dec-2025) • Total Income: Rs 1,538.61 lakhs (vs Rs 5 | 2026-02-11 |
| Quarterly results | 2026-01-23 |
| Quarterly results · Q2 FY26 VALIANT LABORATORIES LIMITED – FINANCIAL RESULTS SUMMARY Q2 FY2025-26 (Half-Year Ended 30 September 2025) --- HEADLINE NUMBERS • 6-month Revenue fr | 2025-11-11 |
| Annual report FY2025 VALIANT LABORATORIES LIMITED – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Total Revenue: ₹13,336.18 Lakhs (FY25) – down from ₹18,205.24 Lakhs | 2025-09-01 |
Readable in the app.
| Announcement | Date |
|---|---|
| Wholly owned subsidiary commences commercial operations at new greenfield facility Valiant Laboratories Limited announced that its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, has begun commercial operations at a new state-of-the-art manufacturing fa | 2025-11-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Valiant Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.